Separately, ValuEngine cut shares of Pulse Biosciences from a buy rating to a hold rating in a research note on Tuesday, September 10th.
Shares of Pulse Biosciences stock opened at $16.53 on Friday. The stock has a market cap of $337.70 million, a price-to-earnings ratio of -7.51 and a beta of 1.84. The firm’s 50-day moving average is $12.40 and its 200 day moving average is $13.81. Pulse Biosciences has a 1 year low of $8.60 and a 1 year high of $19.77. The company has a debt-to-equity ratio of 0.07, a current ratio of 12.92 and a quick ratio of 12.92.
Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Thursday, August 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.04). On average, equities analysts expect that Pulse Biosciences will post -2.29 EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Arbitrage SA increased its position in shares of Pulse Biosciences by 1,082.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,259 shares of the company’s stock valued at $40,000 after purchasing an additional 2,068 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in Pulse Biosciences in the 2nd quarter worth approximately $55,000. Westside Investment Management Inc. purchased a new stake in Pulse Biosciences in the 2nd quarter worth approximately $5,074,000. Vanguard Group Inc. increased its holdings in Pulse Biosciences by 5.2% in the 2nd quarter. Vanguard Group Inc. now owns 463,194 shares of the company’s stock worth $6,114,000 after acquiring an additional 22,800 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in Pulse Biosciences by 17.2% in the 2nd quarter. BlackRock Inc. now owns 734,566 shares of the company’s stock worth $9,695,000 after acquiring an additional 108,059 shares in the last quarter. Institutional investors and hedge funds own 9.87% of the company’s stock.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.
Read More: How to invest in a bear market
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.